Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110 Juliane WitthauerBernd SchlerethBarbara Mayer Preclinical Study 26 September 2008 Pages: 471 - 481
Validation of 70-gene prognosis signature in node-negative breast cancer J. M. Bueno-de-MesquitaS. C. LinnM. J. van de Vijver Preclinical Study 26 September 2008 Pages: 483 - 495
Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy Laura PapiAnna Laura PutignanoMaurizio Genuardi Preclinical Study 27 September 2008 Pages: 497 - 504
Green tea catechins inhibit angiogenesis through suppression of STAT3 activation Hoyee LeongPriya S. MathurGeoffrey L. Greene Preclinical study 28 September 2008 Pages: 505 - 515
Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model Rachel L. RuhlenDana M. WillbrandEdward R. Sauter Preclinical Study 09 September 2008 Pages: 517 - 524
Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance Stella ApostolakiMaria PerrakiDimitris Mavroudis Preclinical Study 19 November 2008 Pages: 525 - 534
HER2 as marker for the detection of circulating tumor cells Volkmar MüllerKlaus Pantel Invited Commentary 30 December 2008 Pages: 535 - 537
Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance Stella ApostolakiMaria PerrakiDimitris Mavroudis Erratum 21 January 2009 Pages: 539 - 539
Quantitative bioimpedance spectroscopy for the assessment of lymphoedema L. C. WardS. CzerniecS. L. Kilbreath Preclinical Study 11 December 2008 Pages: 541 - 547
Lymphatic drainage in the muscle and subcutis of the arm after breast cancer treatment Anthony W. B. StantonStephanie ModiPeter S. Mortimer Preclinical Study 04 December 2008 Pages: 549 - 557
Measuring lymphedema in patients with breast cancer: go with the flow? Kelly K. HuntRobert AskewJanice N. Cormier Invited Commentary 10 February 2009 Pages: 559 - 560
Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial A. SverrisdottirM. NystedtT. Fornander Clinical Trial 20 January 2009 Pages: 561 - 567
Do GnRH analogs protect against ovarian toxicity of chemotherapy? Halle C. F. Moore Invited Commentary 21 February 2009 Pages: 569 - 570
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort N. Lynn HenryJames M. RaeConsortium on Breast Cancer Pharmacogenomics Investigators Clinical Trial 20 January 2009 Pages: 571 - 575
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment Xiaolei ZhouDavid CellaCharles E. Geyer Clinical Trial 20 January 2009 Pages: 577 - 589
Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial Elmar StickelerMaximilian KlarGerald Gitsch Clinical Trial 21 January 2009 Pages: 591 - 598
Never use anthracyclines with trastuzumab: it is time to reconsider the taboo Luca Gianni Invited commentary 23 April 2009 Pages: 599 - 601
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC Stephanie L. HinesBetty MinceyCharles L. Loprinzi Clinical Trial 12 February 2009 Pages: 603 - 609
The effect of transcutaneous electrical nerve stimulation on postmastectomy skin flap necrosis Can AtalayKerim Bora Yilmaz Clinical Trial 15 February 2009 Pages: 611 - 614
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer E. L. MayerA. H. PartridgeE. P. Winer Clinical trial 18 March 2009 Pages: 615 - 623
Axillary web syndrome after axillary dissection in breast cancer: a prospective study María Torres LacombaOrlando Mayoral del MoralÁlvaro Zapico Goñi Clinical trial 21 March 2009 Pages: 625 - 630
A comprehensive evaluation of outcomes for inflammatory breast cancer Relin YangMichael C. CheungLeonidas G. Koniaris Epidemiology 24 January 2009 Pages: 631 - 641
Alcohol intake over the life course and mammographic density Julie D. FlomJennifer S. FerrisMary Beth Terry Epidemiology 29 January 2009 Pages: 643 - 651
Complementary and alternative therapy use before and after breast cancer diagnosis: the Pathways Study Heather GreenleeMarilyn L. KwanLawrence H. Kushi Epidemiology 31 January 2009 Pages: 653 - 665
Haplotypes of XRCC1 and survival outcome in patients with metastatic breast cancer Mary A. BewickMichael S. C. ConlonRobert M. Lafrenie Letter to the editor 07 January 2009 Pages: 667 - 669
Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003 Karen CanfellEmily BanksValerie Beral Letter to the Editor 15 February 2009 Pages: 671 - 673
Test of Hardy–Weinberg equilibrium in breast cancer case-control studies: an issue may influence the conclusions Ke-Da YuGeng-Hong DiZhi-Ming Shao Letter to the Editor 26 February 2009 Pages: 675 - 677
Absence of the BRCA1 del (exons 9–12) mutation in breast/ovarian cancer families outside of Mexican Hispanics Diana TorresMuhammad U. RashidUte Hamann Letter to the Editor 31 March 2009 Pages: 679 - 681
A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer Ava KwongL. P. WongJ. M. Ford Letter to the Editor 08 April 2009 Pages: 683 - 686
